Anebulo Pharmaceuticals, Inc. (ANEB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANEB Stock Price Chart Interactive Chart >
ANEB Price/Volume Stats
| Current price | $2.55 | 52-week high | $7.89 |
| Prev. close | $2.40 | 52-week low | $1.77 |
| Day low | $2.51 | Volume | 3,259 |
| Day high | $2.61 | Avg. volume | 7,959 |
| 50-day MA | $2.72 | Dividend yield | N/A |
| 200-day MA | $3.38 | Market Cap | 65.36M |
Anebulo Pharmaceuticals, Inc. (ANEB) Company Bio
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Latest ANEB News From Around the Web
Below are the latest news stories about ANEBULO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ANEB as an investment opportunity.
Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationAUSTIN, Texas, January 09, 2023--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI") and substance addiction (the "Company" or "Anebulo"), today announced completion of dosing in its randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating ANEB-001 as a potential treatment for ACI in healthy subjects challenged with oral THC. Part B of the Phase 2 |
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday''s Mid-Day SessionGainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL ) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Axcella Health Inc. (NASDAQ: AXLA ) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered its price target from $6 to $2. Camber Energy, Inc. (NYSE: CEI ) shares climbed 103% to $0.1257 after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split. Qumu Corporation (NASDAQ: QUMU ) gained 98.2% to $0.8722 after Enghouse Systems announced it will acquire the company for $0.90 per share in cash. AirNet Technology Inc. (NASDAQ: A... |
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesAUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2022 and recent updates. First Quarter Fiscal Year 2023 and Subsequent Highlights: Announced positive interim data for ANEB-001 from Part B of its Phase 2 clinical trial |
Anebulo Pharmaceuticals GAAP EPS of -$0.11 misses by $0.01Anebulo Pharmaceuticals press release (ANEB): Q1 GAAP EPS of -$0.11 misses by $0.01.Cash was $19.2 million as of September 30, 2022. |
ANEB Price Returns
| 1-mo | 5.21% |
| 3-mo | -6.93% |
| 6-mo | -36.41% |
| 1-year | -61.42% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 5.21% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...